International Practice

Global Access · International Regenerative Medicine Practice

BioCells Medical supports patients from across Europe, Central Asia, the Gulf region, and beyond. Every programme is prepared in our certified cellular therapy laboratory, delivered under direct physician oversight, and built on the same clinical protocols — regardless of where the patient comes from.

Each programme is defined by the BioCells Medical clinical board on the basis of diagnosis, functional status, and safety considerations of the individual patient.

Programme Structure

Clinical Programme

•Certified cellular therapy laboratory preparing every biological product
•Physician oversight across every treatment day of the programme
•Neurology, immunology, and rehabilitation input on every protocol
•Full diagnostic and continuous patient monitoring infrastructure
•Follow-up and rehabilitation pathway integrated into every programme
•Clinical documentation shared with the patient's local physicians

International Patient Support

•Personal coordinator speaking the patient's language
•Visa invitation letter issued whenever required
•Accommodation and transfer logistics handled end-to-end
•Companion accommodation included at no additional cost
•Multilingual clinical communication — five languages in-house, more on request
•Continuity of care maintained after the programme ends

Who the Programme Is Built For

•Patients with ALS, advanced Parkinson's disease, MSA, or dementia
•Patients with progressive or primary progressive multiple sclerosis
•Adults with post-stroke sequelae or severe neuroinflammatory conditions
•Children with autism spectrum disorder or cerebral palsy
•Patients with rare autoimmune conditions and limited conventional options
•Families who require structured international access to regenerative care

Safety & Quality Assurance

All biological materials used in BioCells Medical programmes are prepared exclusively in our certified cellular therapy laboratory in Warsaw, Poland. Every treatment is performed solely by licensed BioCells Medical physicians in accordance with the clinic's internal clinical standards and international medical safety guidelines. No third-party providers are involved in any stage of treatment delivery.

Documented Cases

A selection of documented international patient cases from our clinical practice.

Medical Rationale

ALS is a progressive motor neuron disorder causing rapid neuromuscular degeneration, neuroinflammation, and loss of voluntary function. The objective was to support neuroprotective mechanisms and modulate neuroinflammatory activity in a patient with progressive motor decline.

Treatment Protocol

•Mesenchymal Stem Cell therapy (MSC) — neuroprotective and immunomodulatory support
•T-regulatory cell therapy — immune balance and neuroinflammation control
•Concentrated purified exosomes — intercellular signalling and tissue-support pathways
•Supportive neurofunctional therapy — post-intervention functional adaptation

Follow-Up

A dedicated rehabilitation specialist was assigned. Structured follow-up monitoring was initiated and clinical progress is being systematically documented.

Medical Rationale

Multiple system atrophy is a rare, rapidly progressive neurodegenerative disorder affecting autonomic, cerebellar, and motor systems. Its complexity and rapid trajectory require personalised protocols delivered with precision and close medical oversight.

Treatment Protocol

•Allogeneic MSC infusion — systemic neuroprotective and anti-inflammatory effects
•MSC-derived exosomes — paracrine support for neurological pathways
•T-regulatory cell therapy — modulation of autoimmune components
•Personalised neuro-supportive protocol aligned with disease stage

Follow-Up

The patient remains under continued remote clinical monitoring, with protocol adjustments made in response to functional evolution.

Medical Rationale

Severe COPD with significant limitation of physical capacity and respiratory function. The clinical goal was to support pulmonary tissue regeneration and modulate chronic inflammation without imposing additional physiological stress on an already compromised respiratory system.

Treatment Protocol

•Autologous MSC infusion — pulmonary tissue support and anti-inflammatory activity
•Concentrated exosomes — regenerative biofactor delivery for pulmonary function
•Systemic intravenous administration over two consecutive days
•Full respiratory monitoring throughout the procedure

Follow-Up

Four-month follow-up documented meaningful improvements in exercise tolerance, oxygenation, and chronic cough reduction.

Medical Rationale

Cerebral palsy affecting motor development and functional independence. The protocol was designed around the child's developmental stage, with paediatric-adapted dosing and coordination with the family's existing physiotherapy plan.

Treatment Protocol

•Allogeneic MSC infusion — neuro-developmental support and neuroprotection
•MSC-derived exosomes — intercellular communication and regenerative signalling
•Rehabilitation integration — protocol coordinated with existing physiotherapy plan
•Two-day treatment delivery with paediatric-adapted clinical protocols

Follow-Up

Family-reported progress monitored remotely. Physiotherapy team provided updated notes for ongoing protocol optimisation.

Medical Rationale

Primary progressive MS with accumulating disability and limited response to available disease-modifying therapies. The protocol focused on immunomodulation and neuroprotection in a disease stage where conventional options are largely exhausted.

Treatment Protocol

•Allogeneic MSC infusion — immunomodulatory and neuroprotective approach
•MSC-derived exosomes — targeted molecular support for neurological pathways
•T-regulatory cell therapy — modulation of progressive neuroimmune dysfunction
•Personalised protocol adapted to PPMS disease stage and functional status

Follow-Up

Remote monitoring established. Protocol review scheduled at 3-month interval.

Medical Rationale

Progressive MS with sustained motor and cognitive decline. The patient had completed an initial treatment cycle; subsequent cycles were coordinated to maintain continuity of care and protocol progression.

Treatment Protocol

•Allogeneic MSC infusion — ongoing neuroprotective cycle
•MSC-derived exosomes — continuation of previous regenerative programme
•Neurological status assessed pre- and post-treatment
•Protocol adjusted based on response to prior treatment cycle

Follow-Up

Continuing care pathway. Functional assessment conducted remotely 30 days post-treatment.

Medical Rationale

Autism spectrum disorder with significant behavioural dysregulation and sensory sensitivity. The protocol was designed with paediatric calibration and paced administration to minimise sensory disruption for the child.

Treatment Protocol

•Allogeneic MSC infusion — neuroimmune modulation and neuroplasticity support
•MSC-derived exosomes — neuroprotective and anti-neuroinflammatory signalling
•Paediatric-calibrated dosing and administration pace
•Coordination with the family's existing behavioural therapy team

Follow-Up

Family progress reports collected at 2, 6, and 12 weeks. Communication and behavioural markers tracked.

Medical Rationale

Chronic phase post-stroke sequelae with persisting motor and cognitive deficits. The clinical goal was to support neuroregeneration and vascular repair pathways in a patient with residual neurological impairment.

Treatment Protocol

•Autologous or allogeneic MSC infusion — neuroregeneration and vascular repair support
•MSC-derived exosomes — neuroprotective and anti-inflammatory molecular delivery
•Systemic intravenous administration with structured medical monitoring
•Neurofunctional support integrated with existing rehabilitation programme

Follow-Up

Physiotherapy and neurology teams notified. Remote progress review at 4 and 8 weeks.

Medical Rationale

Autism spectrum disorder in a paediatric patient with severe communication difficulties and environmental sensitivity. The protocol was built around a paediatric-calibrated approach with coordinated support from the child's local therapy team.

Treatment Protocol

•Allogeneic MSC infusion — neuroimmune regulation and neuroplasticity enhancement
•Concentrated exosomes — cell-free regenerative support for brain function
•Paediatric-adapted protocol — dosing, pace, and administration tailored to patient profile
•Coordination with local behavioural therapy team

Follow-Up

Family-reported outcomes collected at regular intervals. Coordination with local therapy providers maintained.

Medical Rationale

ALS with progressive motor neuron degeneration and advancing functional decline. The protocol focused on neuroprotection, inflammatory modulation, and neurotrophic support at an advanced disease stage.

Treatment Protocol

•Autologous MSC therapy — neuroprotection and neurotrophic factor support
•T-regulatory cell therapy — inflammatory modulation in the motor neuron environment
•Concentrated exosomes — complementary regenerative signalling
•Intrathecal or intravenous administration selected based on clinical evaluation

Follow-Up

Clinical monitoring ongoing. Family and attending physician provided structured follow-up data.

Medical Rationale

Relapsing MS with persistent residual disability following a recent relapse. The protocol was tailored to the relapsing disease trajectory, with emphasis on immune stabilisation and remyelination-supporting pathways.

Treatment Protocol

•Allogeneic MSC infusion — immunomodulatory therapy targeting relapsing neuroinflammation
•MSC-derived exosomes — biological support for remyelination pathways
•T-regulatory cell therapy — immune stabilisation in a relapsing disease context
•Monitoring protocol tailored to relapsing disease trajectory

Follow-Up

MRI and clinical evaluation scheduled at 3-month interval. Protocol continuity reviewed at follow-up.

Medical Rationale

Mid-stage Parkinson's disease with motor rigidity, gait instability, and emerging cognitive changes. The protocol focused on dopaminergic neuroprotection, paracrine signalling, and integrated rehabilitation support.

Treatment Protocol

•Allogeneic MSC infusion — dopaminergic neuroprotection and anti-inflammatory support
•MSC-derived exosomes — neuroregeneration and paracrine signalling
•Electro-Neuro Therapy (ENT) if clinically applicable — neurostimulation support
•Personalised rehabilitation plan coordinated with local physiotherapy provider

Follow-Up

Progress assessment conducted at 4 and 8 weeks. Family-reported functional changes documented.

International Patients

International Treatment Access

Patients from across Europe, Central Asia, the Gulf region, and beyond are part of the BioCells Medical programme — with personalised regenerative protocols and full international patient support.

Request Consultation info@biocellsmedical.com

Global Access · International Regenerative Medicine Practice

Each programme is defined by the BioCells Medical clinical board on the basis of diagnosis, functional status, and safety considerations of the individual patient.

Programme Structure

Clinical Programme

•Certified cellular therapy laboratory preparing every biological product
•Physician oversight across every treatment day of the programme
•Neurology, immunology, and rehabilitation input on every protocol
•Full diagnostic and continuous patient monitoring infrastructure
•Follow-up and rehabilitation pathway integrated into every programme
•Clinical documentation shared with the patient's local physicians

International Patient Support

•Personal coordinator speaking the patient's language
•Visa invitation letter issued whenever required
•Accommodation and transfer logistics handled end-to-end
•Companion accommodation included at no additional cost
•Multilingual clinical communication — five languages in-house, more on request
•Continuity of care maintained after the programme ends

Who the Programme Is Built For

•Patients with ALS, advanced Parkinson's disease, MSA, or dementia
•Patients with progressive or primary progressive multiple sclerosis
•Adults with post-stroke sequelae or severe neuroinflammatory conditions
•Children with autism spectrum disorder or cerebral palsy
•Patients with rare autoimmune conditions and limited conventional options
•Families who require structured international access to regenerative care

Safety & Quality Assurance

Documented Cases

A selection of documented international patient cases from our clinical practice.

Medical Rationale

Treatment Protocol

•Mesenchymal Stem Cell therapy (MSC) — neuroprotective and immunomodulatory support
•T-regulatory cell therapy — immune balance and neuroinflammation control
•Concentrated purified exosomes — intercellular signalling and tissue-support pathways
•Supportive neurofunctional therapy — post-intervention functional adaptation

Follow-Up

A dedicated rehabilitation specialist was assigned. Structured follow-up monitoring was initiated and clinical progress is being systematically documented.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — systemic neuroprotective and anti-inflammatory effects
•MSC-derived exosomes — paracrine support for neurological pathways
•T-regulatory cell therapy — modulation of autoimmune components
•Personalised neuro-supportive protocol aligned with disease stage

Follow-Up

The patient remains under continued remote clinical monitoring, with protocol adjustments made in response to functional evolution.

Medical Rationale

Treatment Protocol

•Autologous MSC infusion — pulmonary tissue support and anti-inflammatory activity
•Concentrated exosomes — regenerative biofactor delivery for pulmonary function
•Systemic intravenous administration over two consecutive days
•Full respiratory monitoring throughout the procedure

Follow-Up

Four-month follow-up documented meaningful improvements in exercise tolerance, oxygenation, and chronic cough reduction.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — neuro-developmental support and neuroprotection
•MSC-derived exosomes — intercellular communication and regenerative signalling
•Rehabilitation integration — protocol coordinated with existing physiotherapy plan
•Two-day treatment delivery with paediatric-adapted clinical protocols

Follow-Up

Family-reported progress monitored remotely. Physiotherapy team provided updated notes for ongoing protocol optimisation.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — immunomodulatory and neuroprotective approach
•MSC-derived exosomes — targeted molecular support for neurological pathways
•T-regulatory cell therapy — modulation of progressive neuroimmune dysfunction
•Personalised protocol adapted to PPMS disease stage and functional status

Follow-Up

Remote monitoring established. Protocol review scheduled at 3-month interval.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — ongoing neuroprotective cycle
•MSC-derived exosomes — continuation of previous regenerative programme
•Neurological status assessed pre- and post-treatment
•Protocol adjusted based on response to prior treatment cycle

Follow-Up

Continuing care pathway. Functional assessment conducted remotely 30 days post-treatment.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — neuroimmune modulation and neuroplasticity support
•MSC-derived exosomes — neuroprotective and anti-neuroinflammatory signalling
•Paediatric-calibrated dosing and administration pace
•Coordination with the family's existing behavioural therapy team

Follow-Up

Family progress reports collected at 2, 6, and 12 weeks. Communication and behavioural markers tracked.

Medical Rationale

Treatment Protocol

•Autologous or allogeneic MSC infusion — neuroregeneration and vascular repair support
•MSC-derived exosomes — neuroprotective and anti-inflammatory molecular delivery
•Systemic intravenous administration with structured medical monitoring
•Neurofunctional support integrated with existing rehabilitation programme

Follow-Up

Physiotherapy and neurology teams notified. Remote progress review at 4 and 8 weeks.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — neuroimmune regulation and neuroplasticity enhancement
•Concentrated exosomes — cell-free regenerative support for brain function
•Paediatric-adapted protocol — dosing, pace, and administration tailored to patient profile
•Coordination with local behavioural therapy team

Follow-Up

Family-reported outcomes collected at regular intervals. Coordination with local therapy providers maintained.

Medical Rationale

Treatment Protocol

•Autologous MSC therapy — neuroprotection and neurotrophic factor support
•T-regulatory cell therapy — inflammatory modulation in the motor neuron environment
•Concentrated exosomes — complementary regenerative signalling
•Intrathecal or intravenous administration selected based on clinical evaluation

Follow-Up

Clinical monitoring ongoing. Family and attending physician provided structured follow-up data.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — immunomodulatory therapy targeting relapsing neuroinflammation
•MSC-derived exosomes — biological support for remyelination pathways
•T-regulatory cell therapy — immune stabilisation in a relapsing disease context
•Monitoring protocol tailored to relapsing disease trajectory

Follow-Up

MRI and clinical evaluation scheduled at 3-month interval. Protocol continuity reviewed at follow-up.

Medical Rationale

Treatment Protocol

•Allogeneic MSC infusion — dopaminergic neuroprotection and anti-inflammatory support
•MSC-derived exosomes — neuroregeneration and paracrine signalling
•Electro-Neuro Therapy (ENT) if clinically applicable — neurostimulation support
•Personalised rehabilitation plan coordinated with local physiotherapy provider

Follow-Up

Progress assessment conducted at 4 and 8 weeks. Family-reported functional changes documented.

International Patients

International Treatment Access

Patients from across Europe, Central Asia, the Gulf region, and beyond are part of the BioCells Medical programme — with personalised regenerative protocols and full international patient support.

Request Consultation info@biocellsmedical.com

Global Access · International Regenerative Medicine Practice

Programme Structure

Clinical Programme

International Patient Support

Who the Programme Is Built For

Documented Cases

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Chronic Obstructive Pulmonary Disease (COPD)

Cerebral Palsy (CP)

Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis (progressive form)

Autism Spectrum Disorder (ASD)

Post-Ischaemic Stroke (chronic phase)

Autism Spectrum Disorder (ASD)

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis (relapsing form)

Parkinson's Disease (mid-stage)

International Treatment Access

Global Access · International Regenerative Medicine Practice

Programme Structure

Clinical Programme

International Patient Support

Who the Programme Is Built For

Documented Cases

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Chronic Obstructive Pulmonary Disease (COPD)

Cerebral Palsy (CP)

Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis (progressive form)

Autism Spectrum Disorder (ASD)

Post-Ischaemic Stroke (chronic phase)

Autism Spectrum Disorder (ASD)

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis (relapsing form)

Parkinson's Disease (mid-stage)

International Treatment Access